持续性非卧床腹膜透析患者中庆大霉素的药代动力学
Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis.
作者信息
Pancorbo S, Comty C
出版信息
Antimicrob Agents Chemother. 1981 Apr;19(4):605-7. doi: 10.1128/AAC.19.4.605.
Abstract
Teh pharmacokinetics of gentamicin were studied in seven chronic renal failure patients undergoing continuous ambulatory peritoneal dialysis. Patients received 100 mg of gentamicin in 2 liters of dialysate during an initial pass, and serum and dialysate samples were collected for gentamicin determination. Approximately 49% of the amount introduced into the peritoneal cavity was absorbed systemically during a 6-h cycle. Subsequent clearance of gentamicin from the serum occurred slowly with an elimination half-life of 36 h. Dialysis clearance of gentamicin during continuous ambulatory peritoneal dialysis was 2.94 ml/min.
摘要
在7例接受持续性非卧床腹膜透析的慢性肾衰竭患者中研究了庆大霉素的药代动力学。患者在初次透析时于2升透析液中加入100毫克庆大霉素，并采集血清和透析液样本以测定庆大霉素含量。在6小时的透析周期中，引入腹腔的庆大霉素约49%被全身吸收。随后血清中庆大霉素的清除缓慢，消除半衰期为36小时。持续性非卧床腹膜透析期间庆大霉素的透析清除率为2.94毫升/分钟。
相似文献
1
Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis.
Antimicrob Agents Chemother. 1981 Apr;19(4):605-7. doi: 10.1128/AAC.19.4.605.
2
Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysis.
Nephron. 1982;31(1):37-9. doi: 10.1159/000182611.
3
Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis.
Clin Pharmacol Ther. 1982 Jul;32(1):113-21. doi: 10.1038/clpt.1982.134.
4
Evaluation of gentamicin pharmacokinetics during peritoneal dialysis.
Ther Drug Monit. 1982;4(3):297-300. doi: 10.1097/00007691-198208000-00008.
5
Gentamicin removal during intermittent peritoneal dialysis.
Nephron. 1986;44(1):18-21. doi: 10.1159/000183905.
6
Small and middle molecular weight solute clearance in nocturnal intermittent peritoneal dialysis.
Perit Dial Int. 1999 Nov-Dec;19(6):534-9.
7
Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis.
Antimicrob Agents Chemother. 1983 Aug;24(2):237-9. doi: 10.1128/AAC.24.2.237.
8
Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis.
Antimicrob Agents Chemother. 1984 May;25(5):603-6. doi: 10.1128/AAC.25.5.603.
9
Pharmacokinetics of gentamicin during peritoneal dialysis in children.
Kidney Int. 1976 May;9(5):430-8. doi: 10.1038/ki.1976.53.
10
Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.
Br J Clin Pharmacol. 1985 Feb;19(2):211-7. doi: 10.1111/j.1365-2125.1985.tb02633.x.
引用本文的文献
1
Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review.
Clin Pharmacokinet. 2022 Aug;61(8):1075-1094. doi: 10.1007/s40262-022-01143-0. Epub 2022 Jun 27.
2
Population Pharmacokinetics of Intraperitoneal Gentamicin and the Impact of Varying Dwell Times on Pharmacodynamic Target Attainment in Patients with Acute Peritonitis Undergoing Peritoneal Dialysis.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0167921. doi: 10.1128/AAC.01679-21. Epub 2021 Dec 13.
3
Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study).
Clin J Am Soc Nephrol. 2012 Aug;7(8):1249-56. doi: 10.2215/CJN.12211211. Epub 2012 Jun 14.
4
Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study.
BMC Nephrol. 2009 Dec 16;10:42. doi: 10.1186/1471-2369-10-42.
5
Pharmacokinetic aspects during continuous ambulatory peritoneal dialysis: a literature review.
Pharm Weekbl Sci. 1984 Dec 14;6(6):229-36. doi: 10.1007/BF01954550.
6
Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.
Clin Pharmacokinet. 1985 Sep-Oct;10(5):404-25. doi: 10.2165/00003088-198510050-00003.
7
Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis.
Antimicrob Agents Chemother. 1988 Feb;32(2):236-40. doi: 10.1128/AAC.32.2.236.
8
Co-trimoxazole (sulphamethoxazole plus trimethoprim) peritoneal barrier transfer pharmacokinetics.
Clin Pharmacokinet. 1989 May;16(5):317-25. doi: 10.2165/00003088-198916050-00004.
9
Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.
Clin Pharmacokinet. 1990 Feb;18(2):104-17. doi: 10.2165/00003088-199018020-00002.
本文引用的文献
1
Peritonitis during continuous ambulatory peritoneal dialysis.
Ann Intern Med. 1980 Jan;92(1):7-13. doi: 10.7326/0003-4819-92-1-7.
2
Kinetic model for gentamicin dosing with the use of individual patient parameters.
Clin Pharmacol Ther. 1977 Mar;21(3):362-9. doi: 10.1002/cpt1977213362.
3
Continuous ambulatory peritoneal dialysis.
Ann Intern Med. 1978 Apr;88(4):449-56. doi: 10.7326/0003-4819-88-4-449.
Zotero 插件